Neflamapimod Receives Orphan Drug Designation by FDA for Frontotemporal Dementia

Published Date: 19 Dec 2024

Most recently reported topline data from the RewinD-LB phase 2b trial in patients with dementia with Lewy bodies showed that neflamapimod failed to meet its primary end point and secondary end points.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Nuclear missile workers are contracting cancer: They blame the bases

2.

Mixed Results With Cyclophosphamide in Mismatched Unrelated Stem Cell Transplants

3.

New analysis helps discern benign from malignant thyroid growths

4.

MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information

5.

Even a few mutated cells can significantly impact how blood cancers develop, study finds


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot